Pharmaceuticals Search Engine [selected websites]

Loading

Thursday, August 28, 2008

Stentys : Interim clinical results from "OPEN I" study of its bifurcated stent reported at EuroPCR 2008 international cardiovascular meeting

PARIS, May 19, 2008——Medical device pioneer Stentys announced that clinical results from the ‘OPEN I’ clinical study using its bifurcated stent were presented at last week’s ‘EuroPCR 2008’ international medical meeting on cardiovascular intervention.
The data, presented by Eberhard Grube, M.D., Chief of Cardiology and Angiology at HELIOS Heart Center (Germany) and Principal Investigator of the OPEN I study, included safety results after 30 days post-implantation of the Stentys bifurcated stent in the first 13 patients.
“We were very pleased to report that there were no device-related events at 30 days follow-up of the first 13 patients in our study,” said Dr. Grube. “The Stentys bifurcation stent seems safe and represents a promising technique for optimal treatment of bifurcated lesions. The procedure is identical to known techniques and makes possible excellent reconstruction of the bifurcation.”... [PDF] Stentys' Press Release -

Tuesday, August 12, 2008

Oncodesign and PhenoPro : OncOptima

Tue Jul 22, 2008 - ILLKIRCH, France & DIJON, France - PhenoPro (Illkirch, France) and Oncodesign (Dijon, France) announced their alliance to develop and market "OncOptima". This new joint service integrates the design, the characterization, and the validation of genetically engineered mouse models to evaluate targeted therapies in cancer. This unique partnership combines PhenoPro's broad capabilities and in-depth expertise in mouse model phenotyping, with Oncodesign leadership in preclinical services for translational research in cancer.

OncOptima will provide a comprehensive characterization, including functional, morphological and pharmacological phenotyping. The goal is to obtain validated models corresponding to the targeted therapies in development. Through expertise and technology of both platforms (including MRI, PET, cardio-echography...) it will be easier to further develop preclinical programs and determine the best drug/patient selection in early clinical phases...


...About Oncodesign
Founded in 1995 in Dijon, Oncodesign is a leader in preclinical
and translational evaluation of anti-cancer therapies. With services
ranging from rapid in vitro and in vivo proof-of-concept studies to
mechanistic and translational studies, Oncodesign has worked with over
200 biopharmaceutical companies worldwide and conducted more than 1000
studies. Its unrivalled technological platform, which includes MRI and
PET imaging facilities, together with an extensive choice of tumor
models, positions molecules into the most efficient development
programs. Its pharmacological-based "Qualifying Approach", creates a
continuum between targets, molecules, experimental cellular and animal
models, and human patients.



About PhenoPro

PhenoPro was founded in September 2007 as a spinout of the Mouse
Clinical Institute (Illkirch, France), one of the prime research

institutes in mouse genetic engineering and mouse model phenotyping
worldwide. The company, which is a wholly owned subsidiary of the
Economic Interest Group European Research Center in Biology and
Medicine (Illkirch, France), offers a broad array of mouse models
phenotyping capabilities and phenogenomics expertise in biomedicine to
pharmaceutical and biotechnology companies involved in translational
biopharmaceutical and biomedical research, to understand disease
mechanisms, validate drug targets and identify potential indications
and side effects of candidate drugs.... [PDF] Oncodesign's Press Release -

Wednesday, August 6, 2008

Biométhodes : U.S. and European Patents on Massive Mutagenesis

December 21, 2007 - Biométhodes that it has been granted U.S. Patent N° 7,202,086 and EP Patent N° EP1311670 for its Massive Mutagenesis® technology.

Massive Mutagenesis® technology allows the generation of a large genetic diversity from any gene, mimicking natural evolution but at an accelerated laboratory scale. Massive Mutagenesis® allows the improvement of enzyme activity, stability and specificity. The technology is responsible for several successful Biométhodes projects and thereby a number of natural enzymes have been adapted for industrial use.

Massive Mutagenesis® has been adapted a number of times and one adaptation was patented and published two years ago (Saboulard et al., Biotechniques 2005), thus preceding the present revolution in synthetic biology. This technology, and its application to protein engineering, were published in several articles and have also been the subject of a chapter in a reference book... Biométhodes' Press Release (company/news) -

ImmunID Technologies : Service Research Contract with Sanofi Pasteur

January 14, 2008 - ImmunID Technologies announced the signature of a Contract Research Service with Sanofi Pasteur, the vaccines division of sanofi-aventis Group, and the largest worldwide company entirely devoted to human vaccines.
The innovative technology developed by ImmunID allows the assessment of Human T and B immune repertoires diversity after vaccination...


...About ImmunID
ImmunID Technologies is a young Biotechnology company located in Grenoble, its mission is to develop and commercialise immunomonitoring tests dedicated to pharmaceutical industry and personalized medicine market.
ImmunID offers testing services to monitor the immune repertoire diversity in order to measure the impact of biotherapeutic molecules and to characterize more accurately their efficacy.
ImmunID develops diagnostic products for an early detection of immune related diseases... [PDF] ImmunID Technologies' Press Release -